drugset / Trial / NCT04979585
Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the objective response rate of camrelizumab combined with anlotinib and nab-paclitaxel in patients with untreated advanced mucosal melanoma.
Timeline
- Start
- 2021-07-15
- Primary completion
- 2023-04-14
- Completion
- 2023-08-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Catequentinib | Small molecule | 8 mg | Oral |
| Subject | Nab-paclitaxel | Small molecule | 260 mg/m2 | Intravenous |